试验终止ClinicalTrials.gov(美国登记平台)来源日期:2020-07-22
A Safety Study of Human Cord Blood Derived, Culture Expanded Natural Killer Cell (PNK-007) Infusion With Subcutaneous Recombinant Human IL-2 (rhIL-2) in Adults With Relapsed and/or Refractory Acute Myeloid Leukemia (AML)
编号:NCT02781467登记状态:提前终止企业 / 申办者:Celularity Incorporated
药物 / 成分:PNK-007、Cyclophosphamide、Fludarabine、Human recombinant Interleukin-2 (rhIL-2)
登记的停止原因(原文):Business Decision
查看官方原始记录 ↗试验终止ClinicalTrials.gov(美国登记平台)来源日期:2020-07-22
Acute Labetalol Use in Preeclampsia
编号:NCT03872336登记状态:提前终止企业 / 申办者:Albany Medical College
药物 / 成分:Experimental labetalol dose、Current standard of care
登记的停止原因(原文):Slow enrollment
查看官方原始记录 ↗试验终止ClinicalTrials.gov(美国登记平台)来源日期:2020-07-22
Acute Control of Chronic Hypertension
编号:NCT03877692登记状态:提前终止企业 / 申办者:Albany Medical College
药物 / 成分:Experimental dosing of labetalol、Standard dosing of labetalol
登记的停止原因(原文):Slow enrollment
查看官方原始记录 ↗试验终止ClinicalTrials.gov(美国登记平台)来源日期:2020-07-22
Evaluating the Safety and Efficacy of Inarigivir in Non-cirrhotic, Hepatitis B e Antigen-negative Subjects Infected With HBV Virus and Receiving or Stopping Treatment With a NUC Inhibitor
编号:NCT04023721登记状态:提前终止企业 / 申办者:F-star Therapeutics, Inc.
药物 / 成分:Inarigivir soproxil、Nucleoside/nucleotide (NUC) analogue inhibitors
登记的停止原因(原文):Safety
查看官方原始记录 ↗试验终止ClinicalTrials.gov(美国登记平台)来源日期:2020-07-21
Liver Test Study of Using JKB-122 in Hepatitis C Virus (HCV)-Positive Patients Nonresponsive to Prior Interferon Based Therapies
编号:NCT02293941登记状态:提前终止企业 / 申办者:TaiwanJ Pharmaceuticals Co., Ltd
药物 / 成分:JKB-122 5mg、JKB-122 15mg、JKB-122 35mg、Placebo
登记的停止原因(原文):Completed stage I without pursuing stage II
查看官方原始记录 ↗试验终止ClinicalTrials.gov(美国登记平台)来源日期:2020-07-21
Evaluating the Safety and Efficacy of Inarigivir in Non-cirrhotic Treatment Naive Subjects Infected With Hepatitis B Virus
编号:NCT04059198登记状态:提前终止企业 / 申办者:F-star Therapeutics, Inc.
药物 / 成分:Inarigivir soproxil、Tenofovir alafenamide fumarate (TAF)
登记的停止原因(原文):Evidence of liver injury in a separate Inarigavir study
查看官方原始记录 ↗试验终止ClinicalTrials.gov(美国登记平台)来源日期:2020-07-20
Phase 2/3, Randomized, Double-Masked, Sham-Controlled Trial of QPI-1007 in Subjects With Acute Nonarteritic Anterior Ischemic Optic Neuropathy (NAION)
编号:NCT02341560登记状态:提前终止企业 / 申办者:Quark Pharmaceuticals
药物 / 成分:QPI-1007 Injection - 1.5 mg、QPI-1007 Injection - 3.0 mg、Sham Injection Procedure
登记的停止原因(原文):An interim analysis did not warrant to continue enrollment
查看官方原始记录 ↗试验终止ClinicalTrials.gov(美国登记平台)来源日期:2020-07-17
The Affect of Low-Volume Bowel Preparation for Hospitalized Patients Colonoscopies
编号:NCT01978509登记状态:提前终止企业 / 申办者:Mayo Clinic
药物 / 成分:Low volume prep (Prepopik)、Moderate volume prep (Moviprep)、High volume prep (Golytely)
登记的停止原因(原文):Lack of enrollment
查看官方原始记录 ↗试验终止ClinicalTrials.gov(美国登记平台)来源日期:2020-07-17
Pharmacokinetics of an Aminoglycoside in Hemodialysis Patients.
编号:NCT01982864登记状态:提前终止企业 / 申办者:University Hospital, Limoges
药物 / 成分:Gentamicin
登记的停止原因(原文):Not enough patients
查看官方原始记录 ↗试验终止ClinicalTrials.gov(美国登记平台)来源日期:2020-07-17
Comparison of Loading Strategies With Antiplatelet Drugs in Patients Undergoing Elective Coronary Intervention
编号:NCT02548611登记状态:提前终止企业 / 申办者:LMU Klinikum
药物 / 成分:Prasugrel、Clopidogrel
登记的停止原因(原文):Due to low recruitment
查看官方原始记录 ↗